Ethyl hydrogen (4-{[4-({2-(diethylcarbamoyl)-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate → Ethyl hydrogen (4-{[4-({4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-3-methyl-2-(methylcarbamoyl)phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate

Participants

Reaction Steps

Prepared analogously to Compound 3A using diethyl (4-{[4-({4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-3-methyl-2-(methyl carbamoyl)phenyl}amino)-5-(trifluoromethyl) pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate (Compound 29B). 1H NMR (CD3OD, 400 MHz): δ 8.25 (s, 1H), 7.92 (s, 1H), 7.79 (d, J=8.1 Hz, 1H), 7.69 (s, 1H), 7.64 (d, J=8.3 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 6.99 (s, 1H), 6.59 (d, J=6.8 Hz, 1H), 4.35 (t, J=6.8 Hz, 2H), 3.88 (s, 3H), 3.79 (m, 2H), 3.60 (t, J=6.1 Hz, 2H), 2.87 (d, J=21.5 Hz, 2H), 2.85 (s, 3H), 2.36 (s, 3H), 2.12 (m, 2H), 1.13 (t, J=7.1 Hz, 3H). MS (ESI): m/z=678.23 [M+H]+. UPLC: tR=1.03 min (UPLC-TOF: polar—3 min).

Provenance & Evidence